Mirae Asset Global Investments
SGMT icon

Mirae Asset Global Investments’s Sagimet Biosciences SGMT Stock Holding History

Mirae Asset Global Investments’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1K Buy
2,736
+1,119
+69% +$7.61K ﹤0.01% 1482
2026
Q1 		$8.45K Buy
1,617
+111
+7% +$619 ﹤0.01% 1510
2025
Q4 		$8.92K Buy
+1,506
New +$10.8K ﹤0.01% 1607

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
FRM
Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return

Mirae Asset Global Investments's SGMT Position: Q2 2026 in Review

Mirae Asset Global Investments increased its Sagimet Biosciences (SGMT) stake by 69% in Q2 2026, buying an estimated $7.61K and bringing the position to 2,736 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1482.

Mirae Asset Global Investments first reported a position in SGMT in Q4 2025 and has held it in 3 quarters since. 29 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Mirae Asset Global Investments held 2,736 shares of Sagimet Biosciences worth $21.1K as of Q2 2026.
  • Mirae Asset Global Investments bought 1,119 Sagimet Biosciences shares in Q2 2026, an estimated $7.61K.
  • Sagimet Biosciences made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1482 holding.
  • Mirae Asset Global Investments first reported a position in Sagimet Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 29 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.